Casi pharmaceuticals announces cnct19 (cd19 car-t) granted orphan drug designation by the u.s. fda

Rockville, md. and beijing, jan. 18, 2022 /prnewswire/ -- casi pharmaceuticals, inc. (nasdaq: casi), a u.s. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announced today, that the u.s. food and drug administration (fda) has granted orphan drug designation (odd) to its partner juventas cell therapy ltd (juventas), for cnct19, an investigational cd-19 directed car-t therapy, for the treatment of patients with acute lymphoblastic leukemia (all).
CASI Ratings Summary
CASI Quant Ranking